One of the therapeutic approaches for the treatment of hormone-dependent breast cancer is the inhibition of the enzyme aromatase, by the use of aromatase inhibitors (AIs). However, besides the success of the third-generation AIs, they induce some adverse effects, like the rapid increase of bone loss and the occurrence of endocrine resistance.